AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU

AWM Investment Company Inc. purchased a new position in Aytu BioPharma Inc. (NASDAQ:AYTU) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 619,874 shares of the company’s stock, valued at approximately $1,351,000. AWM Investment Company Inc. owned approximately 6.90% of Aytu BioPharma at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AYTU. FNY Investment Advisers LLC acquired a new stake in Aytu BioPharma in the 2nd quarter valued at about $78,000. Stonepine Capital Management LLC boosted its holdings in shares of Aytu BioPharma by 13.8% during the 1st quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock worth $556,000 after purchasing an additional 56,172 shares during the last quarter. Finally, Kanen Wealth Management LLC purchased a new stake in shares of Aytu BioPharma in the second quarter valued at approximately $1,250,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.

Aytu BioPharma Trading Up 0.9%

NASDAQ AYTU opened at $2.30 on Friday. The firm’s 50-day moving average is $2.19 and its two-hundred day moving average is $2.20. Aytu BioPharma Inc. has a 12 month low of $0.95 and a 12 month high of $2.82. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.23 and a quick ratio of 1.08. The stock has a market capitalization of $23.44 million, a P/E ratio of -0.75 and a beta of 0.28.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%. The company had revenue of $13.89 million for the quarter, compared to analyst estimates of $17.92 million.

Wall Street Analysts Forecast Growth

AYTU has been the topic of a number of analyst reports. Ascendiant Capital Markets lifted their price objective on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Tuesday, October 14th. Wall Street Zen cut shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, November 24th. Finally, Maxim Group reduced their target price on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Aytu BioPharma currently has an average rating of “Hold” and an average target price of $9.33.

Aytu BioPharma Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.